A 69-year-old woman presented with appetite loss, fatigue, and a low-grade fever. She had been receiving certolizumab pegol for rheumatoid arthritis for six years. Computed tomography of the chest showed multiple micronodules in both lungs and bilateral hilar and mediastinal lymphadenopathy. An ophthalmic examination showed the findings of uveitis. Lymphocytosis with an increased CD4/CD8 ratio was seen in the bronchoalveolar lavage fluid. Video-assisted thoracoscopic biopsy specimens obtained from the right lung and a right hilar lymph node showed noncaseous epithelioid cell granulomas. Anti-tumor necrosis factor-α-induced sarcoidosis was diagnosed, and she was successfully treated with cessation of certolizumab pegol and systemic corticosteroid therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492107 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.4275-19 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report.
SAGE Open Med Case Rep
January 2025
Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Hidradenitis suppurativa is a chronic inflammatory disease of the skin with a suppurative-cicatricial outcome affecting the infundibular component of the pilo-sebaceous unit. The lesions are typically localized in the intertriginous and apocrine gland-rich areas. Hidradenitis suppurativa mainly affects patients at a young age and is very often refractory to conventional medical treatment.
View Article and Find Full Text PDFWhat is Rheumatoid factor-from screening to personalized management.
Rheumatology (Oxford)
January 2025
The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan.
The rheumatoid factor (RF) is a representative autoantibody against the crystallizable fragment (Fc) of denatured immunoglobulin (Ig) G that are primarily detected in patients with rheumatoid arthritis (RA). Although five types of tumor necrosis factor (TNF) inhibitors can be used to treat RA, no guidelines are available for selecting the appropriate inhibitor for treatment. High serum RF levels are associated with high disease activity, progressive joint destruction, life prognosis associated with organ damage, decreased treatment responsiveness to TNF inhibitors and other drugs, and low treatment retention rates.
View Article and Find Full Text PDFImpaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study.
RMD Open
December 2024
Rheumatology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands
Objectives: To assess the effect of treatment on haemostatic parameters in patients with early rheumatoid arthritis (RA).
Methods: Patients with newly diagnosed RA started methotrexate and were randomised to additional conventional treatment, certolizumab pegol, abatacept or tocilizumab. Several biomarkers for haemostasis were analysed including parameters of the two global haemostatic assays-overall haemostatic potential (OHP) and endogenous thrombin potential (ETP), as well as single haemostatic factors-fibrinogen, prothrombin fragment 1+2 (F1+2), D-dimer, thrombin activatable fibrinolysis inhibitor (TAFI) and clot lysis time (CLT) in 24 patients at baseline, 12 and 24 weeks after the start of the treatment.
Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti-Tumour Necrosis Factor-α in Patients With Crohn's Disease: A Systematic Literature Review and Meta-Analysis.
United European Gastroenterol J
December 2024
Institute of Clinical Molecular Biology and Clinic for Internal Medicine, Kiel University, Kiel, Germany.
Background: Vedolizumab is approved for the treatment of moderately to severely active Crohn's disease (CD). Real-world evidence is essential for understanding the effectiveness and benefit-risk profile of vedolizumab outside clinical trial settings.
Objective: To identify, systematically review and assess the real-world effectiveness and treatment persistence of vedolizumab in patients with CD, particularly over long-term follow-up periods and among populations with differing treatment experience, and to compare with the treatment persistence of anti-tumour necrosis factor (TNF)-α treatment.
Certolizumab pegol for plaque psoriasis in women of childbearing potential, pregnant or breastfeeding in clinical settings: One-year outcomes from the international noninterventional CIMREAL study.
J Eur Acad Dermatol Venereol
December 2024
Department of Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!